A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

NCT01851070 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Allogeneic Mesenchymal Precursor Cells
DRUG: Normal Saline

Sponsor

Mesoblast, Ltd.

Collaborators

[object Object]